Showing results (11-20 of 16) with videos related to
Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 16 results.
The Journal of Infectious Diseases|June 6, 2023
Breakthrough SARS-CoV-2 Infections in the PROVENT Prevention Trial Were Not Associated With AZD7442 (Tixagevimab/Cilgavimab) Resistant VariantsKevin M Tuffy, Bahar Ahani, Anastasia A Aksyuk, et al.Nature Communications|July 19, 2023
Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trialsBahar Ahani, Kevin M Tuffy, Anastasia A Aksyuk, et al.Science Translational Medicine|January 25, 2022
The SARS-CoV-2 monoclonal antibody combination, AZD7442, is protective in nonhuman primates and has an extended half-life in humansYueh-Ming Loo, Patrick M McTamney, Rosalinda H Arends, et al.Nature Microbiology|September 22, 2021
Genetic and structural basis for SARS-CoV-2 variant neutralization by a two-antibody cocktailJinhui Dong, Seth J Zost, Allison J Greaney, et al.The Lancet. Infectious Diseases|March 20, 2023
Nirsevimab binding-site conservation in respiratory syncytial virus fusion glycoprotein worldwide between 1956 and 2021: an analysis of observational study sequencing dataDeidre Wilkins, Annefleur C Langedijk, Robert Jan Lebbink, et al.Science Advances|March 28, 2025
Preemptive optimization of a clinical antibody for broad neutralization of SARS-CoV-2 variants and robustness against viral escapeFangqiang Zhu, Saravanan Rajan, Conor F Hayes, et al.Pageof 2